Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Free article. Clinical Trial.
Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension.
Cardona-Muñoz EG, López-Alvarado A, Conde-Carmona I, Sánchez-Mejorada G, Pascoe-González S, Banda-Elizondo RG, García-Castillo A, González-Gálvez G, Velasco-Sánchez RG, Vidrio-Velázquez M, Leiva-Pons JL, Villeda-Espinosa E, Guerra-López A, Esturau-Santalo RM. Cardona-Muñoz EG, et al. Among authors: lopez alvarado a. Arch Cardiol Mex. 2017 Oct-Dec;87(4):316-325. doi: 10.1016/j.acmx.2017.01.001. Epub 2017 Feb 10. Arch Cardiol Mex. 2017. PMID: 28209359 Clinical Trial.
In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood.
Ricke WA, Lee CW, Clapper TR, Schneider AJ, Moore RW, Keil KP, Abler LL, Wynder JL, López Alvarado A, Beaubrun I, Vo J, Bauman TM, Ricke EA, Peterson RE, Vezina CM. Ricke WA, et al. Among authors: lopez alvarado a. Toxicol Sci. 2016 Apr;150(2):429-40. doi: 10.1093/toxsci/kfw009. Epub 2016 Feb 9. Toxicol Sci. 2016. PMID: 26865671 Free PMC article.
Treatment of anemia with darbepoetin alfa in systolic heart failure.
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Swedberg K, et al. N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10. N Engl J Med. 2013. PMID: 23473338 Free article. Clinical Trial.
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators. McMurray JJ, et al. Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17. Eur J Heart Fail. 2013. PMID: 23329651 Free PMC article. Clinical Trial.
Basal insulin and cardiovascular and other outcomes in dysglycemia.
ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. ORIGIN Trial Investigators, et al. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11. N Engl J Med. 2012. PMID: 22686416 Free article. Clinical Trial.
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. ORIGIN Trial Investigators, et al. N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11. N Engl J Med. 2012. PMID: 22686415 Free article. Clinical Trial.
12 results